Oncovita and Unither partner on a new prophylactic vaccine
Institut Pasteur biotech spin-off Oncovita and Unither Pharmaceuticals have announced plans to develop and produce a new combined prophylactic vaccine for the prevention of infectious diseases in children. This collaboration combines Measovir, Oncovita’s platform designed to develop highly immunogenic vaccines, with Euroject, Unither Pharmaceuticals’ Blow-Fill-Seal (BFS)-based single-dose… Read More